Portal de recerca
ESTUDIO ALEATORIZADO, DOBLE CIEGO DE GALCANEZUMAB FRENTE A PLACEBO, EN PACIENTES ADULTOS CON MIGRAÑA RESISTENTE AL TRATAMIENTO - ESTUDIO CONQUER.
Dades bàsiques
- Protocol:
- I5Q-MC-CGAW
- EURDRACT:
- 2018-000600-42
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2018
- Any de finalització:
Documents
- No hi ha documents
Participants
Finançadors - Promotors
Resultats de l'Assaig Clínic
1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress
Lainez, JM; (...); Silberstein, S
Review. 10.33588/rn.72s02.2021155. 2021
A 3.9-Mb Deletion on 2p11.2 Comprising the REEP1 Gene Causes Early-Onset Atypical Parkinsonism.
Baviera-Muñoz R; (...); Espinós C
Article. 10.1212/NXG.0000000000000642. 2021
Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom
Diaz-Insa, Samuel; (...); Goadsby, Peter J.
Article. 10.1155/ane/4714514. 2024
Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
Santos-Lasaosa S; (...); Pozo-Rosich P
Article. 10.1016/j.nrleng.2019.03.025. 2022
Cluster headache. Are there differences by gender?
Olivier, M. A.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Characterisation of the management of patients with migraine in the primary care setting in Spain. Analysis of the results of the European My-LIFE anamnesis project
Diaz-Insa, S.; (...); Guerrero, A. L.
Article. 10.1016/j.nrl.2021.10.012. 2023
Characterisation of the management of patients with migraine in the primary care setting in Spain. Analysis of the results of the European My-LIFE anamnesis project.
Diaz-Insa, S; (...); Guerrero, A L
Article. 10.1016/j.nrleng.2021.10.009. 2023
Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders.
Pagonabarraga, Javier; (...); Manzano, Sagrario
Article. 10.3390/brainsci13020318. 2023
Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group
Garcia-Ulla, J.; (...); Irimiao, P.
Article. 10.1016/j.nrl.2023.06.003. 2025
Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group.
Garcia-Ull, J; (...); Irimia, P
Practice Guideline. 10.1016/j.nrleng.2024.02.009. 2024
Diagnostic Efficacy of Genetic Studies in a Series of Hereditary Cerebellar Ataxias in Eastern Spain.
Baviera-Munoz, Raquel; (...); Aller, Elena
Article. 10.1212/NXG.0000000000200038. 2022
Document of revision and updating of medication overuse headache (MOH).
González-Oria C; (...); Santos-Lasaosa S
Review. 10.1016/j.nrl.2020.04.029. 2021
Efectos adversos y complicaciones de la infusión intestinal continua de levodopa-carbidopa en una cohorte de pacientes con enfermedad de Parkinson de un hospital terciario.
Campins-Romeu, Marina; (...); Martinez-Torres, Irene
Article. 10.33588/rn.7405.2021482. 2022
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
Muñoz-Vendrell A; (...); Huerta-Villanueva M
Article. 10.1186/s10194-023-01585-2. 2023
Epilepsy, status epilepticus, and hemiplegic migraine coexisting with a novel SLC4A4 mutation.
Gil-Perotín S; (...); Díaz S
Article. 10.1007/s10072-020-04961-x. 2021
Erenumab vs galcanezumab in a very difficult-to-treat migraine population. Efficacy and safety
Samuel, DI; (...); Jose, NMM
Meeting Abstract. 2021
Erenumab vs galcanezumab in a very difficult-to-treat migraine population. Efficacy and safety
Samuel, DI; (...); Jose, NMM
Meeting Abstract. 2021
MRgFUS subthalamotomy in Parkinson's disease: an approach aimed at minimizing Lesion Volume
Campins-Romeu, Marina; (...); Martinez-Torres, Irene
Article. 10.1038/s41531-024-00843-7. 2024
MRgFUS subthalamotomy in Parkinson's disease: an approach aimed at minimizing Lesion Volume (vol 10, 230, 2024)
Campins-Romeu, Marina; (...); Martinez-Torres, Irene
Correction. 10.1038/s41531-025-00871-x. 2025
Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes.
Mínguez-Olaondo A; (...); Díaz-Insa S
Article. 10.33588/rn.7802.2023176. 2024
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study.
Díaz Insa S; (...); Núñez M
Article. 10.1007/s40122-024-00586-6. 2024
Onabotulinum Toxin A (OnA) as a preventive treatment for non-migraine headaches: a retrospective analysis
Nieves Castellanos, C.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Predictors of =50% and =75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
Caronna, E.; (...); Pozo-Rosich, P.
Meeting Abstract. 2024
Psychological intervention in refractory chronic migraine patients
Zambrano Camina, M.; (...); Diaz Insa, S.
Meeting Abstract. 2024
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E; (...); Pozo-Rosich P
Article. 10.1136/jnnp-2023-333295. 2024
The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom
Diaz-Insa, S; (...); Goadsby, PJ
Meeting Abstract. 2020
THE HUMANISTIC DISEASE BURDEN OF EPISODIC AND CHRONIC MIGRAINE IN FRANCE, SPAIN AND THE UNITED KINGDOM
Diaz-Insa, S; (...); Goadsby, PJ
Meeting Abstract. 2020
Treatment failure with anti-CGRP therapy: should we discontinue the treatment or switch it?
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021
Treatment failure with anti-CGRP therapy: should we discontinue the treatment or switch it?
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021
Which patient related outcome best reflects the willing of a patient to continue with an anti-CGRP monoclonal preventive treatment? A sub-analysis of a prospective study
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021